{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    20,
    25,
    26,
    34,
    41,
    45,
    47,
    48,
    49,
    50,
    52,
    54
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Screening Site Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8",
        "sectionTitle": "Study Assessments and Procedures",
        "description": "Reference from a footnote in Table 1 (SoA) to Section 8 for details on procedures specific to screening sites in the US, mentioned on page 3."
      },
      {
        "id": "ref_2",
        "name": "COVID-19 Vaccine Risk Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.5",
        "sectionTitle": "COVID-19 Vaccine Risk Assessment",
        "description": "Reference from Section 2.3.1.1 to Section 10.5 for potential risks and mitigation measures due to COVID-19 vaccine, found on page 21."
      },
      {
        "id": "ref_3",
        "name": "Dose Modification Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6",
        "sectionTitle": "Dose Modification",
        "description": "Reference from Table 3 (Potential Risks and Mitigation Strategy) to dose modification or discontinuation procedures, found on page 21."
      },
      {
        "id": "ref_4",
        "name": "Adaptive Design Features Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 4",
        "sectionTitle": "Adaptive Protocol Features",
        "description": "Reference from Section 4.1 to Table 4, which describes adaptive features of the study design, found on page 26."
      },
      {
        "id": "ref_5",
        "name": "Dose Modification Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 7",
        "sectionTitle": "ALXN1840 Dose Modifications for Individual Participants",
        "description": "Reference from Table 4 (Adaptive Protocol Features) to Table 7 for dose modification criteria, found on page 27."
      },
      {
        "id": "ref_6",
        "name": "Blood Donation Exclusion Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2",
        "sectionTitle": "Exclusion Criteria",
        "description": "Reference from Table 5 (Participant Lifestyle Considerations) to Section 5.2 regarding blood donation exclusion, found on page 35."
      },
      {
        "id": "ref_7",
        "name": "Contraception Guidance Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.4",
        "sectionTitle": "Contraceptive Guidance and Collection of Pregnancy Information",
        "description": "Reference from Table 5 (Participant Lifestyle Considerations) to Section 10.4 for appropriate contraceptive methods, found on page 35."
      },
      {
        "id": "ref_8",
        "name": "Contraception Inclusion Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1",
        "sectionTitle": "Inclusion Criteria",
        "description": "Reference from Table 5 (Participant Lifestyle Considerations) to Section 5.1 for contraception start times, found on page 35."
      },
      {
        "id": "ref_9",
        "name": "Discontinuation Data Collection Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA)",
        "description": "Reference from Section 7.1 to the SoA for data to be collected at the time of study intervention discontinuation, found on page 42."
      },
      {
        "id": "ref_10",
        "name": "Liver Function Discontinuation Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6",
        "sectionTitle": "Dose Modification",
        "description": "Reference from Section 7.1 to Dose Modification criteria for discontinuing study intervention due to abnormal liver function, found on page 42."
      },
      {
        "id": "ref_11",
        "name": "Pregnancy Discontinuation Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.6",
        "sectionTitle": "Pregnancy",
        "description": "Reference from Section 7.1 to Section 8.2.6 regarding discontinuation due to pregnancy, found on page 42."
      },
      {
        "id": "ref_12",
        "name": "Discontinuation Samples Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 1",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 7.1 to the SoA (Table 1) for samples and data to be collected at study intervention discontinuation, found on page 42."
      },
      {
        "id": "ref_13",
        "name": "Participant Withdrawal Data Collection Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA)",
        "description": "Reference from Section 7.2 to the SoA for data to be collected at the time of study discontinuation, found on page 42."
      },
      {
        "id": "ref_14",
        "name": "ECG Schedule Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA)",
        "description": "Reference from Section 8.2.3 to the SoA for the schedule of 12-lead ECGs, found on page 46."
      },
      {
        "id": "ref_15",
        "name": "QTc Withdrawal Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL",
        "description": "Reference from Section 8.2.3 to Section 7 for QTc withdrawal criteria, found on page 46."
      },
      {
        "id": "ref_16",
        "name": "Laboratory Test List Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference from Section 8.2.4 to Section 10.2 for the list of clinical laboratory tests to be performed, found on page 46."
      },
      {
        "id": "ref_17",
        "name": "AE/SAE Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting",
        "description": "Reference from Section 8.3 to Section 10.3 for procedures on recording, evaluating, follow-up, and reporting AEs and SAEs, found on page 48."
      },
      {
        "id": "ref_18",
        "name": "Lost to Follow-up Definition Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.3",
        "sectionTitle": "Lost to Follow-up",
        "description": "Reference from Section 8.3.3 to the definition of 'lost to follow-up', found on page 48."
      },
      {
        "id": "ref_19",
        "name": "Genetic Testing Prohibition Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.7",
        "sectionTitle": "Genetics",
        "description": "Reference from Section 8.3.6 stating that biobanked samples will not be used for genetic testing, found on page 49."
      },
      {
        "id": "ref_20",
        "name": "PK Sample Collection Schedule Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 1",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 8.5 to the SoA (Table 1) for the schedule of whole blood sample collection for PK analysis, found on page 49."
      },
      {
        "id": "ref_21",
        "name": "Molybdenum Measurement Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1.1",
        "sectionTitle": "Copper and Molybdenum Balance Measurements",
        "description": "Reference from Section 8.5 to Section 8.1.1 for details of molybdenum measured in food, drinks, urine, and feces, found on page 50."
      },
      {
        "id": "ref_22",
        "name": "PD Sample Collection Schedule Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 1",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 8.6 to the SoA (Table 1) for the schedule of blood sample collection for PD analysis, found on page 50."
      },
      {
        "id": "ref_23",
        "name": "Biomarker Details Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.6 and 8.1.1",
        "sectionTitle": "Pharmacodynamics and Copper and Molybdenum Balance Measurements",
        "description": "Reference from Section 8.8 to Sections 8.6 and 8.1.1 for details on various copper and molybdenum biomarkers, found on page 50."
      },
      {
        "id": "ref_24",
        "name": "ECG Time Points Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 1",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9.4.3 to the SoA (Table 1) for specified time points of ECG measurements, found on page 53."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European Union, the US Food and Drug Administration’s (FDA) regulation at 21 CFR part 312.30(b), and any applicable local regulations.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE",
        "pageNumber": 3
      },
      {
        "id": "annot_2",
        "text": "The main reason for preparation of this amendment was to clarify study procedures occurring across different sites in the US, so as to facilitate participant recruitment across different regions of the US, and to lessen inconvenience for participants without compromising the quality of the study.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE",
        "pageNumber": 3
      },
      {
        "id": "annot_3",
        "text": "Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; IB = Investigator’s Brochure; PK = pharmacokinetics; WD = Wilson disease.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 3",
        "pageNumber": 21
      },
      {
        "id": "annot_4",
        "text": "Abbreviations: CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule of Activities.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 5",
        "pageNumber": 35
      },
      {
        "id": "annot_5",
        "text": "Abbreviations: ICF = informed consent form; PD = pharmacodynamic; PK = pharmacokinetic.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 8",
        "pageNumber": 51
      },
      {
        "id": "annot_6",
        "text": "Note: total molybdenum and PUF molybdenum concentration-time profiles on Day 28 after the last 15 mg ALXN1840 dose will be extrapolated to Day 29 (0-24 hr) and subtracted from the observed Day 29 concentration-time profiles after the first 30 mg",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Section 9.4.4",
        "pageNumber": 53
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "Original",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-05-12",
        "description": "Original Protocol"
      },
      {
        "id": "ver_2",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-08-18",
        "description": "Protocol Amendment 1",
        "amendmentNumber": "Amendment 1"
      },
      {
        "id": "ver_3",
        "versionNumber": "2.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-03-19",
        "description": "Protocol Amendment 2",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_4",
        "versionNumber": "3.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-08-31",
        "description": "Protocol Amendment 3",
        "amendmentNumber": "Amendment 3"
      },
      {
        "id": "ver_5",
        "versionNumber": "3.1",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-03-18",
        "description": "Protocol Amendment 3.1 (US)",
        "amendmentNumber": "Amendment 3.1 (US)"
      }
    ],
    "summary": {
      "referenceCount": 24,
      "annotationCount": 6,
      "versionCount": 5
    }
  }
}